Clavis Pharma announces Successful Completion of Share Offering
(Thomson Reuters ONE) - Oslo, Norway, 18 August 2009Clavis Pharma ASA (OSE:CLAVIS) today announced the successfulcompletion of the subsequent share offering, following the privateplacement in June that raised NOK 129 million in gross proceeds. Thesubsequent offering of 650,000 shares, each with a par value of NOK1.00, at subscription price of NOK 12.00 per share, wasoversubscribed by approximately 100 percent, and resulted in grossproceeds of NOK 7.8 million.In total, the private placement and subsequent offering in 2009raised NOK 136.8 million in gross proceeds for Clavis Pharma to fundthe further development of its pipeline of novel anticancer drugcandidates.Reference is made to the announcement of the subsequent offering on15 July and 17 July 2009 and the prospectus published on 20 July 2009concerning an offering of up to 650,000 shares, each with a par valueof NOK 1.00, at a subscription price of NOK 12.00 per share withpre-emptive rights for Clavis Pharma ASA shareholders as of 25 June2009, except shareholders who were allocated new shares in theprivate placement.The subscription period for the subsequent offering ended on Friday,14 August 2009 and the Board of Clavis Pharma ASA has decided todayto allocate 650,000 shares in connection with the subsequentoffering. Allocation letters will be sent to the subscribers todaywith payment for the allocated shares due on 21 August 2009.Following registration of the share capital increase in relation tothe subsequent offering, the issued share capital of Clavis PharmaASA will be NOK 24,975,650 divided on 24,975,650 shares with a parvalue of NOK 1.00 per share.The new shares to be issued in the subsequent offering will not betradable until the shares have been fully paid and the share capitalincrease has been registered in the Norwegian Register of BusinessEnterprises.Carnegie ASA and DnB NOR Markets managed the offering.ContactGeir Christian Melen, CEOOffice : +47 24 11 09 65Mobile : +47 91 30 29 65E-mail : geir.christian.melen(at)clavispharma.comGunnar Manum, CFOOffice : +47 24 11 09 71Mobile : +47 95 17 91 90E-mail : gunnar.manum(at)clavispharma.comFor international press enquiries:Mark Swallow / Nina Enegren / David DibleCitigate Dewe RogersonOffice : +44 207 282 2948E-mail : clavispharma(at)citigatedr.co.ukAbout Clavis PharmaClavis Pharma ASA is an oncology focused pharmaceutical company usingits proprietary Lipid Vector Technology (LVT) platform to create NewChemical Entities (NCEs), by significantly improving alreadyestablished drugs. The improvements are achieved by chemicallybinding specific unsaturated lipids to existing, and well understood,approved pharmaceuticals. Data generated suggests the resultingpatentable NCEs offer improved efficacy and reduced side effectsthrough enhanced pharmacokinetic properties, greater tissuepenetration and, in many cases, additional modes of action.Clavis Pharma's objective is to develop its drug candidates untilsignificant value has been created and proof of principle in man hasbeen shown. For further clinical development and commercialisation ofthe products, Clavis Pharma will enter into strategic partnershipswith established pharmaceutical or biotech companies. The company'sproduct portfolio includes four new cancer drugs: Elacytarabine is inClinical Phase II, Intravenous CP-4126 is in Clinical Phase II, OralCP-4126 in Phase I, and CP-4200 is in preclinical development.Results indicate that these products have promising potential forseveral cancer indications within solid tumours and leukaemia.The shares of Clavis Pharma ASA are listed on the Oslo Stock Exchange(ticker: CLAVIS). Additional information on Clavis Pharma can befound at: http://www.clavispharma.com/.DisclaimerThe information contained herein shall not constitute an offer tosell or the solicitation of an offer to buy, nor shall there be anysale of the securities referred to herein in any jurisdiction inwhich such offer, solicitation or sale would be unlawful prior toregistration, exemption from registration or qualification under thesecurities laws of any such jurisdiction.This news release contains forward-looking statements and forecastsbased on uncertainty, since they relate to events and depend oncircumstances that will occur in the future and which, by theirnature, will have an impact on results of operations and thefinancial condition of Clavis Pharma. There are a number of factorsthat could cause actual results and developments to differ materiallyfrom those expressed or implied by these forward-looking statements.Theses factors include, among other things, risks associated withtechnological development, the risk that research & development willnot yield new products that achieve commercial success, the impact ofcompetition, the ability to close viable and profitable businessdeals, the risk of non-approval of patents not yet granted anddifficulties of obtaining relevant governmental approvals for newproducts.No expressed or implied representations or warranties are givenconcerning Clavis Pharma or the accuracy or completeness of theinformation or projections provided herein, and no claims shall bemade by the recipient hereof by virtue of this Information Memorandumor the information or projections contained herein. Anyrepresentations or warranties made to an investor in Clavis Pharmawill be subject to separate sale and purchase agreements to benegotiated between the parties.Clavis Pharma(TM) is a registered trademark of Clavis Pharma ASA.http://hugin.info/136972/R/1335621/317463.pdfThis announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
Datum: 18.08.2009 - 16:28 Uhr
Sprache: Deutsch
News-ID 4835
Anzahl Zeichen: 0
contact information:
Town:
London
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 312 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Clavis Pharma announces Successful Completion of Share Offering"
steht unter der journalistisch-redaktionellen Verantwortung von
Clavis Pharma ASA (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
